The companies will develop blood-based genetic assay to be used for research in diagnosis and prognosis of Alzheimer’s disease and Mild Cognitive Impairment (MCI).
Cytox CEO Dr Richard Pither said: "Our early research studies developed with our partners at University College London and University of Birmingham suggest that by using a customised genetic variation (SNP) panel, it may be possible to better assess the risk of an individual developing AD or MCI.
"The Axiom genotyping platform from Affymetrix, a highly robust, cost-effective, and fast turn-around time genotyping platform, is ideally suited for use in a blood-based test for researchers interested in AD and MCI risk stratification and longer term diagnostic and prognostic use."
Cytox is involved in developing assays for risk assessment and prediction of dementia, while Affymetrix provides translational research and diagnostic solutions for pharmaceutical, diagnostic, and biotechnology firms.
